Following on from information provided to NICE by the company in April 2020, the appraisal of Elotuzumab for untreated multiple myeloma [ID966] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 966
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 23 November 2022 | Discontinued. Following on from information provided to NICE by the company in April 2020, the appraisal of Elotuzumab for untreated multiple myeloma [ID966] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 08 April 2020 | Note added to the project documents |
| 17 January 2020 | Note added to the project documents |
| 16 September 2019 | Note added to the project documents |
| 09 November 2018 | Note added to the project documents |
| 29 January 2018 | In progress. In progress |
| 07 December 2016 | Suspended. Topic suspended. |
| 22 July 2016 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual